Cytokine filtration in lung transplantation
Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)
NA · Lund University Hospital · NCT05526950
This study is testing whether using a special device to filter out harmful substances during lung transplants can help patients have fewer complications and live longer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 116 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Lund University Hospital (other) |
| Locations | 1 site (Lund, Skåne County) |
| Trial ID | NCT05526950 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of cytokine adsorption devices in lung transplantation to reduce early complications such as primary graft dysfunction (PGD). It is a randomized controlled trial comparing outcomes in patients receiving lung transplants with and without the cytokine filtration intervention. The goal is to gather preliminary data on the efficacy of this approach in improving patient survival and reducing complications associated with lung transplants. The study focuses on the inflammatory response that occurs immediately after transplantation and aims to mitigate its effects.
Who should consider this trial
Good fit: Ideal candidates are individuals eligible for double lung transplantation who meet the study's inclusion criteria.
Not a fit: Patients under 18 years old, those with previous organ transplants, or those requiring immunosuppressive therapy at the time of surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates and reduce complications for lung transplant recipients.
How similar studies have performed: Previous studies in heart and kidney transplantation have shown success with cytokine adsorption, suggesting potential for similar outcomes in lung transplantation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Eligibility to undergo double lung transplantation at either trial site Exclusion Criteria: 1. Age \<18 years 2. Previous organ transplantation 3. Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined as: 1. Cyclosporine, Tacrolimus, Everolimus, or Sirolimus, minimum 1 month of treatment prior to transplantation and active treatment at the time of transplantation. 2. Any form of antibody-based treatment that is known for having an immunomodulatory effect taken up to 1 week before transplantation. 4. Non-consent
Where this trial is running
Lund, Skåne County
- Sandra Lindstedt — Lund, Skåne County, Sweden (RECRUITING)
Study contacts
- Principal investigator: Sandra Lindstedt, MD, PhD — Skånes universitetssjukhus Lund
- Study coordinator: Sandra Lindstedt, MD,PhD
- Email: sandra.lindstedt_ingemansson@med.lu.se
- Phone: +46737220580
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Transplant Failure, Lung Transplant, Complications